Life Sciences Corporate Partnering & Licensing
#1 Globally for Pharma and Biotech Licensing Deals
EpimAb + Innovent Enter $120 Million Bispecific Antibody Partnership
Learn More
Exelixis and Ipsen Enter into Exclusive Licensing Agreement
Learn More
Bristol Meyers Squibb enters an exclusive worldwide license and collaboration agreement with Five Prime Therapeutics for CSF1R antibody program.
Learn More
Ionis Pharmaceuticals Enters Collaboration Agreement with Janssen Biotech
Learn More
World-Leading Universities form Joint Venture with Global Pharmaceutical Companies to Further Therapeutic Innovation
Learn More
Why Cooley
- 40+ professionals across the US, UK and China exclusively focused on corporate partnering, licensing, M&A and other commercial transactions specific to life sciences companies
- Involvement with hundreds of transactions across various technologies and stages of product development
- Team includes prior pharmaceutical marketing specialists, business consultants, biotech researchers and in-house counsel at life sciences companies
- Well-versed in the business, regulatory and commercial issues inherent in transactions, with the ability to call on a team of intellectual property, regulatory, reimbursement, tax, antitrust and other specialists as needed
- Essentially, we serve as outsourced business/corporate development for many of our clients
Recognition
- "Highly Recommended” law firm for licensing & collaborations in 2017 & 2018 — LMG Life Sciences
- BioPharm Insight: #1 in Biotechnology and Pharmaceutical Licensing League Table Report
- Allicense Deal of the Year: 15 Cooley transactions awarded or nominated since 2000
- Chambers USA: Band 1 for Life Sciences
According to industry peers, the licensing, tax and inversion, private investment, capital market and M&A work performed by Cooley is top tier.
– LMG Life Sciences
ViewHide related contacts
+-
Listing Returned 0 Results.
ViewHide related news
+-
Listing Returned 0 Results.
ViewHide related events
+-
Listing Returned 0 Results.